JP2007527904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527904A5 JP2007527904A5 JP2007502390A JP2007502390A JP2007527904A5 JP 2007527904 A5 JP2007527904 A5 JP 2007527904A5 JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007502390 A JP2007502390 A JP 2007502390A JP 2007527904 A5 JP2007527904 A5 JP 2007527904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- alkoxy
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 52
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- -1 hydroxy, fluoromethyl Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000005961 cardioprotection Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55125404P | 2004-03-08 | 2004-03-08 | |
| PCT/GB2005/000885 WO2005085245A1 (en) | 2004-03-08 | 2005-03-08 | Pyrrolopyridine-2-carboxylic acid hydrazides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007527904A JP2007527904A (ja) | 2007-10-04 |
| JP2007527904A5 true JP2007527904A5 (enExample) | 2008-02-07 |
Family
ID=34919586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007502390A Withdrawn JP2007527904A (ja) | 2004-03-08 | 2005-03-08 | グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7884112B2 (enExample) |
| EP (1) | EP1725555B1 (enExample) |
| JP (1) | JP2007527904A (enExample) |
| AT (1) | ATE483708T1 (enExample) |
| DE (1) | DE602005023965D1 (enExample) |
| ES (1) | ES2353309T3 (enExample) |
| WO (1) | WO2005085245A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| JP5277407B2 (ja) * | 2007-12-14 | 2013-08-28 | 名古屋市 | ポリ乳酸用造核剤及びポリ乳酸樹脂組成物 |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| US8946426B2 (en) | 2009-02-06 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| ES2431619T3 (es) | 2009-05-07 | 2013-11-27 | Janssen Pharmaceuticals, Inc. | Derivados de indazol y aza-indazol sustituidos como moduladores de gamma-secretasa |
| NZ597505A (en) | 2009-07-15 | 2013-05-31 | Janssen Pharmaceuticals Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| US9145399B2 (en) | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
| ES2536442T3 (es) | 2011-03-24 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa |
| JP6068464B2 (ja) | 2011-07-15 | 2017-01-25 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | γ−セクレターゼ調節剤としての新規な置換インドール誘導体 |
| ES2585009T3 (es) | 2012-05-16 | 2016-10-03 | Janssen Pharmaceuticals, Inc. | Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer |
| CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
| AU2014206834B2 (en) | 2013-01-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8618188D0 (en) | 1986-07-25 | 1986-09-03 | Ici Plc | Diamine compounds |
| US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| GB8813356D0 (en) | 1988-06-06 | 1988-07-13 | Ici Plc | Polypeptide compounds |
| US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
| US5821241A (en) | 1994-02-22 | 1998-10-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5885967A (en) | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
| DE69530683T2 (de) | 1994-03-11 | 2004-03-25 | Pharmacopeia, Inc. | Sulfonamid derivate und deren verwendung |
| GB9408117D0 (en) | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| US6001811A (en) | 1994-11-21 | 1999-12-14 | Cortech Inc. | Serine protease inhibitors--N-substituted derivatives |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| TW394764B (en) | 1995-02-14 | 2000-06-21 | Mitsubishi Chemcal Corp | Oxygen-containing heterocyclic derivatives |
| DE19516483A1 (de) | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU5772296A (en) | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
| JP3314938B2 (ja) | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| US6297269B1 (en) | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| CA2502764A1 (en) | 1995-08-22 | 1997-03-06 | Japan Tobacco Inc. | Amide compounds |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| IL119466A (en) | 1995-11-03 | 2001-08-26 | Akzo Nobel Nv | Thrombin inhibitors, their preparation and pharmaceutical compositions containing them |
| US6107309A (en) | 1995-11-13 | 2000-08-22 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0874638A4 (en) | 1995-11-13 | 1999-07-21 | Smithkline Beecham Corp | HEMATOREGULATORS |
| FR2744361B1 (fr) | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif |
| EP1007544A1 (en) | 1996-02-13 | 2000-06-14 | Akzo Nobel N.V. | Serine protease inhibitors |
| WO1997031016A2 (en) | 1996-02-23 | 1997-08-28 | Ariad Pharmaceuticals, Inc. | New inhibitors of sh2-mediated processes |
| IL120310A (en) | 1996-03-01 | 2002-02-10 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceuticals containing them |
| US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| US6342516B1 (en) | 1998-07-31 | 2002-01-29 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| AU4796700A (en) | 1999-05-13 | 2000-12-05 | Dupont Pharmaceuticals Research Laboratories, Inc. | Ureido-substituted cyclic amine derivatives and their use as drug |
| DE60023878T2 (de) | 1999-05-18 | 2006-07-20 | Teijin Ltd. | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| AU5788800A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| EP1201239A4 (en) | 1999-08-04 | 2004-12-08 | Teijin Ltd | CCR3 CYCLIC AMINE ANTAGONISTS |
| EP1088824B1 (en) | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| AU2001227122A1 (en) | 2000-01-29 | 2001-08-07 | Lg Chem Investment Ltd. | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof |
| US6797504B1 (en) | 2000-09-08 | 2004-09-28 | Dendreon San Diego Llc | Inhibitors of serine protease activity of matriptase or MTSP1 |
| JP4327398B2 (ja) | 2000-02-23 | 2009-09-09 | ジーランド・ファーマ・ア／エス | 新規な抗不整脈性ペプチド |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| WO2001094310A1 (en) | 2000-06-07 | 2001-12-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| WO2001096346A1 (en) | 2000-06-14 | 2001-12-20 | Eli Lilly And Company | Tricyclic compounds as mrp1-inhibitors |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| US6277877B1 (en) | 2000-08-15 | 2001-08-21 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors |
| AU2001279612A1 (en) | 2000-08-18 | 2002-03-04 | H. Lundbeck, A/S | Substituted polyamine compounds |
| CA2321348A1 (en) | 2000-09-27 | 2002-03-27 | Blaise Magloire N'zemba | Aromatic derivatives with hiv integrase inhibitory properties |
| GB2369117A (en) | 2000-11-17 | 2002-05-22 | Warner Lambert Co | Bombesin receptor antagonists |
| RU2003120070A (ru) | 2000-12-06 | 2004-12-27 | Авентис Фармаа Дойчланд Гмбх (De) | Производные гуанидина и амидина в качестве ингибиторов фактора ха |
| JPWO2003037864A1 (ja) * | 2001-10-29 | 2005-02-17 | 日本たばこ産業株式会社 | インドール化合物及びその医薬用途 |
| DE602004028122D1 (de) * | 2003-05-21 | 2010-08-26 | Prosidion Ltd | Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
-
2005
- 2005-03-08 ES ES05717953T patent/ES2353309T3/es not_active Expired - Lifetime
- 2005-03-08 JP JP2007502390A patent/JP2007527904A/ja not_active Withdrawn
- 2005-03-08 WO PCT/GB2005/000885 patent/WO2005085245A1/en not_active Ceased
- 2005-03-08 EP EP05717953A patent/EP1725555B1/en not_active Expired - Lifetime
- 2005-03-08 AT AT05717953T patent/ATE483708T1/de not_active IP Right Cessation
- 2005-03-08 DE DE602005023965T patent/DE602005023965D1/de not_active Expired - Lifetime
- 2005-03-08 US US10/591,895 patent/US7884112B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007527904A5 (enExample) | ||
| JP2007530696A5 (enExample) | ||
| WO2006046039A3 (en) | Tetracyclic indole derivatives as antiviral agents | |
| KR20180080189A (ko) | 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물 | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2008514732A5 (enExample) | ||
| JP2005502621A5 (enExample) | ||
| RU2006132463A (ru) | Антагонисты рецептора хемокина | |
| JP2010501478A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2006524225A5 (enExample) | ||
| BRPI0719828A2 (pt) | Mono-hidrato de 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamo-il} amino)-3-fluorofenóxi]-n-metilpiridina-2-carboxamid a | |
| EP2397476A3 (en) | Indole derivative having PGD2 receptor antagonist activity | |
| TW200528459A (en) | Azabenzofuran substituted thioureas; inhibitors of viral replication | |
| AR036939A1 (es) | Antagonistas de la hormona de concentracion de melanina (mch) composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o en combinacion, para la elaboracion de un medicamento para el tratamiento de obesidad | |
| JP2002535401A5 (enExample) | ||
| JP2010520154A (ja) | 神経変性疾患のためのａｍｐａレセプターアンタゴニストおよびｎｍｄａレセプターアンタゴニスト | |
| JP2002519425A5 (enExample) | ||
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| JP2000159790A5 (enExample) | ||
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
| JP2009502770A5 (enExample) | ||
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler |